IJMS | Free Full-Text | c-Abl Tyrosine Kinase Is Regulated Downstream of the Cytoskeletal Protein Synemin in Head and Neck Squamous Cell Carcinoma Radioresistance and DNA Repair
Opening the door to the development of novel Abl kinase inhibitors | Future Medicinal Chemistry
JCI - Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency
The role of non-receptor tyrosine kinases c-Abl and c-Src | Yosef Shaul's Lab
Regulation of the c-Abl and Bcr–Abl tyrosine kinases | Nature Reviews Molecular Cell Biology
Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis: Cell
NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors | PNAS
BCR-ABL1 and the Philadelphia chromosome - Part 3: The BCR-ABL fusion protein - YouTube
Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase: Cell
Differential signaling networks of Bcr–Abl p210 and p190 kinases in leukemia cells defined by functional proteomics | Leukemia
Proposed mechanisms for the regulation of c-Abl tyrosine kinase. The... | Download Scientific Diagram
Mechanism of action of BCR (breakpoint cluster region)-ABL (Abelson 1... | Download Scientific Diagram
A Split-Abl Kinase for Direct Activation in Cells - ScienceDirect
IJMS | Free Full-Text | Blockade of Y177 and Nuclear Translocation of Bcr- Abl Inhibits Proliferation and Promotes Apoptosis in Chronic Myeloid Leukemia Cells
STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia - The Lancet Oncology
Bcr-Abl tyrosine-kinase inhibitor - Wikipedia
Identification of the Direct Substrates of the ABL Kinase via Kinase Assay Linked Phosphoproteomics with Multiple Drug Treatments | Journal of Proteome Research
Structure, Regulation, Signaling, and Targeting of Abl Kinases in Cancer - Oliver Hantschel, 2012
The SH2 Domain Regulates c-Abl Kinase Activation by a Cyclin-Like Mechanism and Remodulation of the Hinge Motion | PLOS Computational Biology
Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia - The Lancet